{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+mixture&page=2",
    "query": {
      "intervention": "Saline mixture",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+mixture&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T04:04:14.549Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03582085",
      "title": "Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Bacillus Calmette Guerin Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-01-01",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 1,
      "location_summary": "Charlestown, Massachusetts",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03582085"
    },
    {
      "nct_id": "NCT01681095",
      "title": "Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Myocardial Ischemia",
        "Coronary Disease",
        "Heart Diseases",
        "Valvular Heart Disease"
      ],
      "interventions": [
        {
          "name": "Custodiol HTK",
          "type": "DRUG"
        },
        {
          "name": "Cold Blood Cardioplegia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marc Sakwa, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2012-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681095"
    },
    {
      "nct_id": "NCT05294640",
      "title": "Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Eyelid Tumor",
        "Eyelid Bump",
        "Eyelid Deformity",
        "Eyelid Abscess",
        "Eyelid Boil",
        "Eyelid Papilloma",
        "Anesthesia, Local",
        "Ophthalmology"
      ],
      "interventions": [
        {
          "name": "0.9% Bacteriostatic Local Anesthetic Injection",
          "type": "DRUG"
        },
        {
          "name": "1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection",
          "type": "DRUG"
        },
        {
          "name": "Eyelid Lesion Removal",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 95,
      "start_date": "2022-05-17",
      "completion_date": "2023-02-21",
      "has_results": true,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05294640"
    },
    {
      "nct_id": "NCT00656110",
      "title": "Neuroma Injections to Treat Restless Legs Syndrome - RCT",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Restless Legs Syndrome"
      ],
      "interventions": [
        {
          "name": "equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml",
          "type": "DRUG"
        },
        {
          "name": "Normal saline - 1ml",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lowcountry Infectious Diseases",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2008-04",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2009-03-10",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00656110"
    },
    {
      "nct_id": "NCT01812044",
      "title": "Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Strabismus"
      ],
      "interventions": [
        {
          "name": "subtenons anesthetic - preservative-free bupivacaine 0.75%",
          "type": "DRUG"
        },
        {
          "name": "topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel",
          "type": "DRUG"
        },
        {
          "name": "topical control - 0.5 cc of Hypromellose 0.3% gel",
          "type": "DRUG"
        },
        {
          "name": "subtenons control - 0.5 cc of Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "1 Year to 7 Years"
      },
      "enrollment_count": 57,
      "start_date": "2013-03",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-04-26",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01812044"
    },
    {
      "nct_id": "NCT05559671",
      "title": "Safety of the Herpes Zoster Subunit Vaccine in Lupus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Herpes Zoster Subunit (HZ/su) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 224,
      "start_date": "2023-12-21",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 2,
      "location_summary": "New York, New York • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05559671"
    },
    {
      "nct_id": "NCT04116775",
      "title": "Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Fecal microbiota transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Julie Graff, MD",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2019-10-30",
      "completion_date": "2023-10",
      "has_results": false,
      "last_update_posted_date": "2022-06-23",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04116775"
    },
    {
      "nct_id": "NCT01575405",
      "title": "A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "Rectal formulation (RF) of tenofovir 1% gel",
          "type": "DRUG"
        },
        {
          "name": "Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel",
          "type": "DRUG"
        },
        {
          "name": "Universal HEC Placebo Gel Formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ian McGowan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2013-03",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-11-07",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01575405"
    },
    {
      "nct_id": "NCT01264601",
      "title": "Safe Administration of Flu Vaccine to Egg Allergic Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Egg Allergy"
      ],
      "interventions": [
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "6 Months to 24 Years"
      },
      "enrollment_count": 31,
      "start_date": "2010-10",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2017-10-26",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264601"
    },
    {
      "nct_id": "NCT02538341",
      "title": "Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Inflammatory Arthritis",
        "Arthritis",
        "Psoriatic Arthritis",
        "Psoriasis",
        "Ankylosing Spondylitis",
        "Enteropathic Arthritis",
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Herpes Zoster (HZ) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 617,
      "start_date": "2016-05",
      "completion_date": "2020-12",
      "has_results": true,
      "last_update_posted_date": "2021-11-23",
      "last_synced_at": "2026-09-28T04:04:14.549Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02538341"
    }
  ]
}